Delving into the Latest Updates on Centre Hospitalier Regional de Nancy with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Neoplasms

Diagnostic radiopharmaceuticals

Peptide Conjugate Radionuclide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	1
Peptide Conjugate Radionuclide	1

Top 5 Target	Count

SSTR(Somatostatin receptor)	1

Targeted Radionuclide Therapy (TRT) is a contemporary approach to radiation oncology, aiming to deliver the maximal destructive radiation dose via cancer-targeting radiopharmaceutical. Radioactive ligands for the prostate-specific membrane antigen (PSMA) have emerged for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Normal organ and tumor dose can be assessed by a series of cross-sectional whole-body SPECT scans, however, these require a large amount imaging time and are often not feasible in routine clinical practice.
An alternative is to generate a 3D time integrated activity (TIA) map per patient based on the PBPK and the pre-therapy imaging

Start Date30 Nov 2024

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

100 Clinical Results associated with Centre Hospitalier Regional de Nancy

Login to view more data

0 Patents (Medical) associated with Centre Hospitalier Regional de Nancy

Login to view more data

14

Literatures (Medical) associated with Centre Hospitalier Regional de Nancy

01 Jan 2022·Brain and Spine

Management of cavernous sinus meningiomas: Consensus statement on behalf of the EANS skull base section

Article

Author: Daniel, Roy T ; Schroeder, Henry W S ; Gardner, Paul A ; Corniola, Marco V ; Sindou, Marc ; Froelich, Sebastien ; Cavallo, Luigi M ; Régis, Jean ; Cornelius, Jan F ; Tatagiba, Marcos ; Roche, Pierre-Hugues ; Meling, Torstein R ; Bruneau, Michaël ; Messerer, Mahmoud ; Kawase, Takeshi ; Gentili, Fred ; Schwartz, Theodore H ; Paraskevopoulos, Dimitrios

IntroductionThe evolution of cavernous sinus meningiomas (CSMs) might be unpredictable and the efficacy of their treatments is challenging due to their indolent evolution, variations and fluctuations of symptoms, heterogeneity of classifications and lack of randomized controlled trials. Here, a dedicated task force provides a consensus statement on the overall management of CSMs.Research questionTo determine the best overall management of CSMs, depending on their clinical presentation, size, and evolution as well as patient characteristics.Material and methodsUsing the PRISMA 2020 guidelines, we included literature from January 2000 to December 2020. A total of 400 abstracts and 77 titles were kept for full-paper screening.ResultsThe task force formulated 8 recommendations (Level C evidence). CSMs should be managed by a highly specialized multidisciplinary team. The initial evaluation of patients includes clinical, ophthalmological, endocrinological and radiological assessment. Treatment of CSM should involve experienced skull-base neurosurgeons or neuro-radiosurgeons, radiation oncologists, radiologists, ophthalmologists, and endocrinologists.Discussion and conclusionRadiosurgery is preferred as first-line treatment in small, enclosed, pauci-symptomatic lesions/in elderly patients, while large CSMs not amenable to resection or WHO grade II-III are candidates for radiotherapy. Microsurgery is an option in aggressive/rapidly progressing lesions in young patients presenting with oculomotor/visual/endocrinological impairment. Whenever surgery is offered, open cranial approaches are the current standard. There is limited experience reported about endoscopic endonasal approach for CSMs and the main indication is decompression of the cavernous sinus to improve symptoms. Whenever surgery is indicated, the current trend is to offer decompression followed by radiosurgery.

01 Feb 1997·Transplantation ProceedingsQ4 · MEDICINE

Toxoplasmosis in kidney transplant recipients: A life-threatening but treatable disease

Q4 · MEDICINE

Article

Author: Hestin, D ; Georges, E ; Renoult, E ; Biava, M F ; Frimat, L ; Hulin, C ; Kessler, M

01 Feb 1996·Transplantation proceedingsQ4 · MEDICINE

Transmission of toxoplasmosis by renal transplant: a report of four cases.

Q4 · MEDICINE

Article

Author: Hestin, D ; Biava, M F ; Kessler, M ; Renoult, E ; Hulin, C ; Frimat, L

100 Deals associated with Centre Hospitalier Regional de Nancy

Login to view more data

100 Translational Medicine associated with Centre Hospitalier Regional de Nancy

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data